Eli Lilly and Company (LLY)
Updated data for Lillys Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
Updated data for Lillys Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
📈 **POSITIVE** • Medium confidence analysis (75%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (86%) **Content type:** Clinical